Particle.news
Science ❯ Biology ❯ Molecular Biology
Protein Engineering Protein Structure Fluorescent Proteins Ubiquitin Antioxidants TRPM8 Protein Structure Prediction CK1δ CENP-A Gliomedin NMDAR Protein Polilaminina Molecular Structures GALNTL5 TRPV4 Protein Dynamin 1xA Protein Folding Circadian Rhythms RNA-Binding Proteins Chaperones Catch-Bonds Isoforms Protein Function Poxviral Core Protein A10 Liquid-Liquid Phase Separation Enzyme Activity SMYD2 Ankyrin-2 PKZILLA-1 PP2A-B55α Amyloid-beta Amino Acid Sequences Aurora A Kinase KIF1A Protein Design Cyclins and CDKs Misfolded Proteins Drug Development Protein Misfolding PTGES3 RAS Proteins Amino Acids DNA Repair Proteins Ribosomes Microproteins Midkine Fractals PspA Protein Inducible Nitric Oxide Synthase (iNOS) Peptide Sequencing Actin Filaments PARP2 Protein Drug Design Interleukin-33 (IL-33) Erythropoietin Proteasomal Function USP50 CCN1 Amyloid Proteins Integrins SORLA Protein Titin Mutations AP2A1 Protein Antifreeze Proteins Protein Degradation NuSAP Glycoproteins D1 Protein Collagen Gephyrin Paxillin Alpha-Synuclein G Protein-Coupled Receptors
The drug’s cyclophilin A 'molecular glue' mechanism targets a broad set of RAS mutations, with an ongoing Phase 3 trial set to decide a lung‑cancer approval.
